Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Machine learning-based prediction of remimazolam induction dose for painless gastroscopy
ChiCTR2200066628Phase 4Not yet recruiting
- Sponsor
- Jiaxing Second Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in None, sponsored by Jiaxing Second Hospital. Primary endpoints: Total dosage of remimazolam for successful gastroscope insertion and Times of addition of remimazolam. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2200066628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066628.